May 2025

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops, laser therapy, and invasive surgeries, have been the mainstay for managing intraocular pressure (IOP). However, these methods often come with limitations, including side effects, compliance issues, and variable efficacy. […]

Understanding Age-Related Glaucoma Progression: Key Insights Glaucoma is a leading cause of irreversible blindness worldwide, particularly affecting older adults. As we age, the risk of developing glaucoma increases, making it crucial to understand how this condition progresses over time. Early detection and proper management can help preserve vision and improve quality of life. In this

Surge in Three Major Eye Diseases Linked to Blindness In recent years, the prevalence of eye diseases leading to blindness has seen a concerning rise. With aging populations, increased screen time, and environmental factors, experts warn that conditions like glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are becoming more widespread. Understanding these diseases, their

PreserFlo MicroShunt Complications Lead to Corneal Damage and Surgical Revision The PreserFlo MicroShunt has been widely adopted as a minimally invasive surgical option for glaucoma patients, offering an alternative to traditional trabeculectomy. While the device has shown promise in reducing intraocular pressure (IOP), emerging reports highlight complications such as corneal damage and the need for

National Reconstruction Fund Invests $27M in Glaucoma Treatment Innovation The National Reconstruction Fund (NRF) has announced a groundbreaking investment of $27 million into cutting-edge glaucoma treatment innovation. This significant funding aims to accelerate research, development, and commercialization of advanced therapies to combat glaucoma—a leading cause of irreversible blindness worldwide. The move underscores the government’s commitment

Brandon Capital and Labor’s NRF Invest $40M in Glaucoma Biotech PolyActiva The biotechnology sector continues to attract significant investment as innovative companies push the boundaries of medical science. In a major development, Brandon Capital and Labor’s National Reconstruction Fund (NRF) have jointly invested $40 million in PolyActiva, an Australian biotech firm specializing in glaucoma treatments.

Glaucoma Treatment Market to Hit USD 14.1 Billion by 2033 with 5.35% CAGR Growth The global glaucoma treatment market is poised for significant expansion, projected to reach USD 14.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.35%. This growth is fueled by rising prevalence of glaucoma, advancements in treatment options,

iStent Infinite Trial: Key Clinical Insights for Glaucoma Treatment Glaucoma remains one of the leading causes of irreversible blindness worldwide, affecting millions of people. While traditional treatments like eye drops, laser therapy, and trabeculectomy have been the mainstay, minimally invasive glaucoma surgeries (MIGS) are revolutionizing patient care. Among these, the iStent Infinite has emerged as

Early Diagnosis of Childhood Glaucoma with Swept-Source AS-OCT Childhood glaucoma is a rare but serious eye condition that can lead to permanent vision loss if not diagnosed and treated early. Traditional diagnostic methods often fall short in detecting subtle changes in the anterior segment of the eye, especially in young children. However, advancements in imaging

Preventable Glaucoma Vision Loss Hindered by Treatment Costs Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Yet, what makes this condition even more tragic is that much of the vision loss it causes is preventable with timely diagnosis and treatment. Unfortunately, the high cost of glaucoma care creates significant barriers